Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time

Orgenesis to Present at the 2019 Janney Healthcare Conference

Orgenesis Inc. shares  soared 19% in premarket trade Monday, after the U.S.

Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech

Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Orgenesis Inc. (ORGS) Report Negative Q1 Earnings? What You Should Know

News for Orgenesis Stock (ORGS)